Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: Three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 3, 2012, Pages 385-394

  Rodriguez, Alfredo E ^a,b   Rodriguez Granillo, Alfredo M ^b   Antoniucci, David ^c   Mieres, Juan ^a   Fernandez Pereira, Carlos ^a   Rodriguez Granillo, Gaston A ^a   Santaera, Omar ^d   Rubilar, Bibiana ^a   Palacios, Igor F ^e,f   Serruys, Patrick W ^g  

^a Sanatorio Otamendi   (Argentina)

^b Centro de Estudios en Cardiologia Intervencionista (CECI)   (Argentina)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Clinica IMA   (Argentina)

^e Argentina Society for Cardiac Interventions (CACI)   (Argentina)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g CARDIALYSIS   (Netherlands)

Author keywords

complications; drug delivery; percutaneous coronary interventions; restenosis; thrombosis

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ADULT; AGED; ARGENTINA; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DEVICE SAFETY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GINGIVA PAIN; HEART INFARCTION; HOSPITAL COST; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; STROKE; THERAPY EFFECT;

ADMINISTRATION, ORAL; AGED; ARGENTINA; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; STENTS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865634871     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23352     Document Type: Article

References (32)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico RA,. Randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE,. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
4. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M,. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): An 18-month analysis. Lancet 2007; 370: 1552-1559. (Pubitemid 350018894)
5. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE,. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004; 110: 508-514. (Pubitemid 39031165)
6. Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llaurado C, Russo M, Virmani R, Ambrose JA,. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol 2003; 15: 581-584. (Pubitemid 37288544)
7. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J,. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004; 44: 1386-1392. (Pubitemid 39303938)
8. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa Murray G, Dirschinger J, Heemann U, Schömig A,. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790-795. (Pubitemid 39096005)
9. Rodríguez AE, Rodríguez Alemparte M, Vigo CF, Fernández Pereira C, Llauradó C, Vetcher D, Pocovi A, Ambrose J,. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: Results of the Argentina single centre study (ORAR trial). Heart 2005; 91: 1433-1437. (Pubitemid 41531818)
10. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G,. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The prospective, randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006; 47: 1522-1529.
11. Stojkovic S, Ostojic M, Nedeljkovic M, Stankovic G, Beleslin B, Vukcevic V, Orlic D, Arandjelovic A, Kostic J, Dikic M, Tomasevic M,. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation. Catheter Cardiovasc Interv 2010; 75: 317-325.
12. Ferrero V, Tomai F, Versaci F, Feola M, Proietti I, Rognoni A, Ghini A, Gaspardone A, Vacca G, De Luca L, Vassanelli C, Ribichini F,. Long term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetics patients with elevated C-reactive protein levels. EuroIntervention 2009; 5: 250-254.
13. Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW,. Percutaneous coronary interventions with oral sirolimus plus bare metal stents has comparable efficacy and safety to treatment with drug eluting stents, but with significant cost saving: Follow up results from the randomized, controlled ORAR III study. EuroIntervention 2009; 5: 255-264.
14. Gold MR, Siegel JE, Russell LB, and, Weinstein MC,. Cost-Effectiveness in Health and Medicine. Oxford University Press; 1996.
15. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S III, Domanski M, McKinlay S, Fuster V,. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial. Am Heart J 2008; 155: 215-221.
16. Rodriguez AE, Mieres J, Fernandez-Pereira C, Vigo CF, Rodriguez-Alemparte M, Berrocal D, Grinfeld L, Palacios I,. Coronary stent thrombosis in the current drug-eluting stent era: Insights from the ERACI III trial. J Am Coll Cardiol 2006; 47: 205-207 (Pubitemid 43005187)
17. Vranckx P, Kint P-P, Morel M-A, Van Es G-A, Serruys PW, Cutlip D,. Identifying stent thrombosis, a critical appraisal of the Academic Research Consortium (ARC) consensus definition: A lighthouse and as a toe in the water. EuroIntervention 2008; 4 (Suppl. C): C39-C44.
18. Rodriguez AE, Grinfeld L, Fernandez-Pereira C, Mieres J, Rodriguez Alemparte M, Berrocal D, Rodriguez-Granillo AM, Vigo CF, Russo Felsen M, O'Neill W, Palacios I,. Revascularization strategies of coronary multiple vessel disease in the drug eluting stent era: One year follow-up results of the ERACI III trial. EuroIntervention 2006; 2: 53-60.
19. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME,. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223. (Pubitemid 41352109)
20. Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, Fernandez-Pereira C, Curotto V, Rodriguez-Granillo A, O'Neill W, Palacios IF,. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 2007; 28: 2118-2125. (Pubitemid 47517450)
21. Ong AT, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, Serruys PW,. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Eur Heart J 2006; 27: 2996-3003 (Pubitemid 44950444)
22. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME,; BASKET Investigators Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005; 366: 921-929. Erratum in: Lancet 2005; 366: 2086. (Pubitemid 41265666)
23. Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ,. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol 2009; 103: 338-344.
24. Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, Kastrati A, Schömig A, Mehilli J,. Long term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. J Am Coll Cardiol Interv 2009; 2: 1142-1148.
25. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO,. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297: 1992-2000. (Pubitemid 46740351)
26. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS,. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297: 2001-2009. (Pubitemid 46740352)
27. Hanna NN, Gaglia MA Jr, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R,. Three-year outcomes following sirolimus-versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 2010; 106: 504-510
28. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME,. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 2005; 295: 1215-1223. (Pubitemid 41352109)
29. Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, Lortkipanidze N, Cicorella N, Biondi Zoccai G, Sirbu V, Izzo A, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ,. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186-194.
30. Caixeta A, Lansky AJ, Serruys PW, Hermiller JB, Ruygrok P, Onuma Y, Gordon P, Yaqub M, Miquel-Hebert K, Veldhof S, Sood P, Su X, Jonnavithula L, Sudhir K, Stone GW,. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents a pooled analysis from the SPIRIT II (a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) and SPIRIT III (a clinical evaluation of the investigational device XIENCE V everolimus eluting coronary stent system [EECSS] in the treatment of subjects with de novo native coronary artery lesions) randomized trials, JACC. Cardiovasc Interv 2010; 3: 1220-1228.
31. Lord SJ, Howard K, Allen F, Marinovich L, Burgess DC, King R, Atherton JJ,. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust 2005; 183: 464-471. (Pubitemid 41671779)
32. Bischof M, Briel M, Bucher A, Nordmann A,. Cost effectiveness of DES in US medicare system: A cost utility analysis of 3 years clinical follow up data. Value in Health 2009; 12: 649-656.